Healthcare Industry News: Ampion
News Release - November 14, 2016
IDEXX Welcomes Healthcare Technology Veteran Pat Venters as Chief Marketing OfficerWESTBROOK, Maine, Nov. 14, 2016 -- (Healthcare Sales & Marketing Network) -- IDEXX Laboratories, Inc. (IDXX), the global leader in veterinary diagnostics, software, and water microbiology testing, today announced that Pat Venters has joined the company as Vice President and Chief Marketing Officer. Venters will be responsible for the company's commercial marketing efforts, including global responsibility for its marketing centers of excellence. Venters' role includes support of demand generation initiatives, market research and analytics, digital and social marketing, and brand and marketing communications.
"Pat Venters brings exceptional business expertise and marketing innovation to this new leadership role at IDEXX. She is an accomplished marketing executive, successful at developing strategies that have driven growth and customer engagement at the heads of some of the world's most successful technology companies, including Hewlett Packard, Philips Healthcare, and GE," said Jon Ayers, Chairman and Chief Executive Officer of IDEXX Laboratories.
"Pat's strategic marketing leadership will help further drive customer insights and chAmpion customer needs as part of the company's ongoing effort to strengthen the value proposition of our innovative products and services," Ayers continued.
A key element of IDEXX's strategy is to pursue attractive double-digit growth in its served markets. Over the last several years, IDEXX has invested to broaden and strengthen its commercial presence, including establishing several go-direct strategies in important regions. This has enabled IDEXX to deepen its customer relationships and educate the industry on the power of diagnostic testing to increase the standard of veterinary care.
Venters joins IDEXX with 25 years of healthcare marketing experience, most recently serving as Chief Marketing Officer for GE Healthcare's ultrasound line of business, where she led strategic business initiatives to drive customer engagement and growth of a multibillion-dollar business.
Prior to her role at GE, Venters held various marketing leadership positions at Philips Healthcare, including Vice President of Professional Services and Solutions and Vice President of Global Oncology and Women's Health, where she developed transformational marketing solutions that decreased costs and improved access and quality of care.
For more information about the IDEXX leadership team, go to idexx.com/corporate/corporate-governance.html
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 7,000 people and offers products to customers in over 175 countries.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov, at various SEC reference facilities in the United States and via the Company's website at idexx.com).
Source: IDEXX Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.